Drug – bio-affecting and body treating compositions – Plant material or plant extract of undetermined constitution...
Reexamination Certificate
2003-02-07
2008-03-11
Hoffman, Susan Coe (Department: 1654)
Drug, bio-affecting and body treating compositions
Plant material or plant extract of undetermined constitution...
C424S773000, C424S774000, C424S779000
Reexamination Certificate
active
07341745
ABSTRACT:
A method for decreasing nicotine and other substance use in humans is disclosed. Tetrahydroberberine (THB) and its analogs, l-Tetrahydropalmatine (l-THP) and l-Stepholidine (l-SPD), are present in and can be isolated from several plants in the Magnoliidae superorder. According to the disclosed method, THB and its analogs are used to block nicotine-induced DA release, and modulate heterologous or homoeric expression of human nicotinic acetylcholine receptors (nAChR) in humans. Specifically, THB exhibits bi-directory modulation of α4β2-nAChR-mediated currents induced by nicotine. THB also shows predominant inhibition on homologously expressed α7-nAChR function. Thus, according to the disclosed method, THB is used to simultaneous blockade midbrain DA system function, the brain reward center, and neuronal α4β2- and α7-nAChR function, the major nicotine targets in the brain. Therefore, THB and its analogs serve as a novel class of natural compounds to decrease nicotine dependence in humans. Furthermore other substances, such as alcohol, cocaine, and opiates, also operate by triggering the brain reward center, resulting in a cycle of substance or alcohol abuse. THB and its analogs can be used to decrease use of substances such as alcohol, cocaine, and opiates. Finally, because THB and its analogs are DA antagonists, THB and its analogs can also be used as a treatment for Parkinson's Disease, Alzheimer's Disease and Schizophrenia.
REFERENCES:
patent: 3843788 (1974-10-01), Iwasa et al.
patent: 4517172 (1985-05-01), Southard
patent: 4590061 (1986-05-01), Southard
patent: 4767861 (1988-08-01), Boulware
patent: 4818533 (1989-04-01), Boulware et al.
patent: 5242926 (1993-09-01), Hsieh et al.
patent: 5308619 (1994-05-01), Schneider et al.
patent: 5411733 (1995-05-01), Hozumi et al.
patent: 5417979 (1995-05-01), Fan et al.
patent: 5547956 (1996-08-01), Qu et al.
patent: 5616324 (1997-04-01), Foster et al.
patent: 5876728 (1999-03-01), Kass et al.
patent: 6210680 (2001-04-01), Jia et al.
patent: 6217880 (2001-04-01), Lan
patent: 6239139 (2001-05-01), Kim et al.
patent: 6255317 (2001-07-01), Kim et al.
patent: 6933291 (2005-08-01), Qi et al.
patent: 2001/0000731 (2001-05-01), Jia et al.
patent: 2001/0038863 (2001-11-01), Jaenicke et al.
patent: 2002/0031559 (2002-03-01), Liang et al.
patent: 2002/0038863 (2002-04-01), Walker
patent: 2002/0039587 (2002-04-01), Tao
patent: 2002/0041906 (2002-04-01), Tao
patent: 2002/0068095 (2002-06-01), Qi et al.
patent: 2002/0068097 (2002-06-01), Basu
patent: 2000-191530 (2000-07-01), None
Blanchfield et al. (Natural Product Letters (1993), vol. 3, No. 4, pp. 305-312).
Vetulani (Polish Journal of Pharmacology (2001), vol. 53, pp. 415-434).
www.bioimages.org.uk/HTML/T79.HTM; accessed Apr. 21, 2004.
Pan et al. (Yiyao Gongye (1988), vol. 19, No. 7, pp. 319-320).
Zhang et al. (Life Sciences (1998), vol. 63, No. 7, pp. 537-544).
Jie Wu, Guo-Zhang Jin, “Tetrahydroberberine suppresses dopamine-induced potassium current in acutely dissociated CA1 pyramidal neurons from rat hippocampus,”Neuroscience Letters207 (1996), pp. 155-158.
Jie Wu, Guo Zhang Jin, “Tetrahydroberberine inhibits acetylcholine-induced K+current in acutely dissociated rat hippocampal CA1 pyramidal neurons,”Neuroscience Letters222 (1997), pp. 115-118.
Jie Wu, Guo Zhang Jin, “Tetrahydroberberine blocks membrane K+channels underlying its inhibition of intracellular message-mediated outward currents in acutely dissociated CA1 neurons from rat hippocampus,”Brain Research775 (1997), pp. 214-218.
Masayuki Niwa, Iiiroyuki Mibu, Masakatsu Nozaki, Kaito Tsurumi, Hajime Fujimura, “Dopaminergic Unique Affinity of Tetrahydroberberine and 1-Tetrahydroberberine-d-Camphor Sulfonate,”Pharmacology1991, pp. 329-336.
Iwasa K, Nanba H, Lee Du, Kang Si, “Structure-activity relationships of protoberberines having antimicrobial activity,” NCBI,National Library of Medicine, Abstract of Planta Medica (1998) vol. 64, No. 8, pp. 748-751.
Sheng WD, Jiddawi MS, Hong XQ, Abdulla SM, “Treatment of chloroquine-resistant malaria using pyrimethamine in combination with berberine, tetracycline or cotrimoxazole,” NCBI,National library of medicine, Abstract of East Afr. Med. J. (1997) vol. 74, No. 5, pp. 283-284.
“A Randomized Controlled Trial of the Use of Craniosacral Osteopathic Manipulative Treatment and of Botanical Treatment in Recurrent otitis media in Children,” ClinicalTrials.gov, Jul. 2002.
Arizona Health Consulting, LLC
Atkins Robert D.
Hoffman Susan Coe
Quarles & Brady LLP
LandOfFree
Method for decreasing nicotine and other substance use in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for decreasing nicotine and other substance use in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for decreasing nicotine and other substance use in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3980398